| |
| |
|
| Insider
Information: |
Sharp Shalini |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
215,117 |
|
|
Indirect Shares
|
104,270 |
|
|
| Direct
Value |
$4,317,035 |
|
|
|
Indirect Value
|
$46,244 |
|
|
| Total
Shares |
319,387 |
|
|
| Total
Value |
$4,363,279 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 537.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agenus Inc |
AGEN |
Director |
2013-01-30 |
81,311 |
2015-09-28 |
104,270 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
EVP, Finance |
2020-10-14 |
97,812 |
|
0 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
35,000 |
2021-02-10 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2021-03-26 |
0 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
994 |
2024-05-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
130 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2016-10-19 |
4 |
OE |
$0.82 |
$9,780 |
D/D |
12,000 |
57,387 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2017-02-27 |
4 |
AS |
$80.14 |
$961,680 |
D/D |
(12,000) |
51,887 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2017-02-27 |
4 |
OE |
$0.82 |
$9,780 |
D/D |
12,000 |
63,887 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-10-31 |
4 |
OE |
$0.82 |
$9,780 |
D/D |
12,000 |
62,128 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-03-18 |
4 |
OE |
$6.86 |
$82,320 |
D/D |
12,000 |
81,157 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-03-18 |
4/A |
OE |
$6.86 |
$82,320 |
D/D |
12,000 |
81,126 |
0 |
- |
|
| AGEN |
Agenus Inc |
Director |
– • – |
2012-06-19 |
4 |
A |
$5.26 |
$66,870 |
D/D |
12,713 |
82,590 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-05-30 |
4 |
AS |
$70.17 |
$912,171 |
D/D |
(13,000) |
57,174 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2009-07-15 |
4 |
S |
$1.76 |
$23,397 |
D/D |
(13,271) |
192,020 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-08-17 |
4 |
S |
$88.24 |
$1,271,073 |
D/D |
(14,378) |
98,187 |
0 |
% |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2011-03-09 |
4 |
A |
$0.98 |
$14,294 |
D/D |
14,586 |
293,579 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-03-18 |
4 |
AS |
$70.00 |
$1,036,000 |
D/D |
(14,800) |
66,357 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-03-18 |
4/A |
AS |
$70.00 |
$1,036,000 |
D/D |
(14,800) |
66,326 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
• • – |
2024-01-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,222) |
0 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-18 |
4 |
OE |
$70.57 |
$1,382,678 |
D/D |
19,593 |
122,929 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-18 |
4 |
S |
$73.29 |
$1,612,260 |
D/D |
(21,985) |
100,944 |
0 |
% |
|
| AGEN |
Agenus Inc |
Director |
– • – |
2015-09-28 |
4 |
A |
$4.59 |
$100,980 |
I/I |
22,000 |
104,270 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2012-01-03 |
4 |
A |
$2.17 |
$48,003 |
D/D |
22,121 |
63,765 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2016-11-09 |
4 |
OE |
$0.82 |
$19,560 |
D/D |
24,000 |
69,387 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2016-11-09 |
4 |
AS |
$70.06 |
$1,708,894 |
D/D |
(24,000) |
45,387 |
0 |
- |
|
| NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
– • – |
2021-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2008-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
26,201 |
55,890 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2009-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
26,201 |
90,091 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2011-01-20 |
4 |
A |
$0.94 |
$27,161 |
D/D |
28,895 |
275,243 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-09-16 |
4 |
OE |
$0.81 |
$176,317 |
D/D |
31,843 |
99,089 |
0 |
- |
|
130 Records found
|
|
Page 5 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
